Status:
UNKNOWN
Independent and Combined Effects of Resistance Exercise Training and β-hydroxy β-methylbutyrate Plus Vitamin D
Lead Sponsor:
University of Illinois at Urbana-Champaign
Collaborating Sponsors:
Metabolic Technologies Inc.
Conditions:
Aging
Skeletal Muscle
Eligibility:
FEMALE
45-60 years
Phase:
NA
Brief Summary
During middle-age, humans begin to lose muscle mass and strength. With increasing age the deterioration of muscle health is associated with a decline in quality of life and the loss of independence. β...
Detailed Description
To determine if HMB+VitD supplementation is an effective strategy to help prevent the loss of skeletal muscle size, skeletal muscle function and body composition in middle-aged women, forty eight wome...
Eligibility Criteria
Inclusion
- Women between 45 and 60 years old
- Women with a BMI \< 35 kg/m2
- Sedentary (\< 30 minutes of structured physical activity 3 times per week)
- Weight stable for 3 months prior (+/- 5kg)
Exclusion
- Body mass index \> 35 kg/m2
- Type 1 or Type 2 diabetes
- Uncontrolled hypertension
- Active cancer, cancer in remission, or having received treatment for any form of cancer in the previous 5 years
- Cardiovascular disease (e.g., peripheral artery disease and peripheral vascular disease)
- Uncontrolled thyroid function
- Chronic and/or regular consumption of medication known to influence skeletal muscle metabolism
- Use of Vitamin D (\>2000 IU) or β-hydroxy β-methylbutyrate
- Tobacco use
- Any condition that limits exercise training (e.g., chronic obstructive pulmonary disease, neuromuscular disorder, moderate or severe cognitive impairment, Alzheimer's disease, vertigo, dizziness)
- High alcohol consumption defined as more than 8 drinks per week for women
- Unwilling to undergo any study-related procedures
- Pregnancy
- Abnormal liver or kidney enzymes determined in blood chemistry panel
- Bleeding/clotting disorders or blood thinning medications (e.g., warfarin, heparin)
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT03848741
Start Date
April 1 2019
End Date
April 1 2021
Last Update
July 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Freer Hall
Urbana, Illinois, United States, 61822